A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia

AIM: Evaluation of the Nativis Voyager(®), an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). MATERIALS & METHODS: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical u...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Michael, Dowling, Anthony, Thien, Christopher, Priest, Emma, Morgan Murray, Donna, Kesari, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Clinical Trial Evaluation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499017/
https://www.ncbi.nlm.nih.gov/pubmed/30727742
http://dx.doi.org/10.2217/cns-2018-0017
_version_ 1783415729952915456
author Murphy, Michael
Dowling, Anthony
Thien, Christopher
Priest, Emma
Morgan Murray, Donna
Kesari, Santosh
author_facet Murphy, Michael
Dowling, Anthony
Thien, Christopher
Priest, Emma
Morgan Murray, Donna
Kesari, Santosh
author_sort Murphy, Michael
collection PubMed
description AIM: Evaluation of the Nativis Voyager(®), an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). MATERIALS & METHODS: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2–4 months. RESULTS: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams. CONCLUSION: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.
format Online
Article
Text
id pubmed-6499017
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-64990172019-05-06 A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia Murphy, Michael Dowling, Anthony Thien, Christopher Priest, Emma Morgan Murray, Donna Kesari, Santosh CNS Oncol Clinical Trial Evaluation AIM: Evaluation of the Nativis Voyager(®), an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). MATERIALS & METHODS: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2–4 months. RESULTS: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams. CONCLUSION: The data suggest that the Voyager is safe and feasible for the treatment of rGBM. Future Medicine Ltd 2019-02-07 /pmc/articles/PMC6499017/ /pubmed/30727742 http://dx.doi.org/10.2217/cns-2018-0017 Text en © 2019 Nativis, Inc. This work is licensed under a Creative Commons Attribution-NonCommercial NonDerivative 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Clinical Trial Evaluation
Murphy, Michael
Dowling, Anthony
Thien, Christopher
Priest, Emma
Morgan Murray, Donna
Kesari, Santosh
A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title_full A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title_fullStr A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title_full_unstemmed A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title_short A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
title_sort feasibility study of the nativis voyager(®) device in patients with recurrent glioblastoma in australia
topic Clinical Trial Evaluation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499017/
https://www.ncbi.nlm.nih.gov/pubmed/30727742
http://dx.doi.org/10.2217/cns-2018-0017
work_keys_str_mv AT murphymichael afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT dowlinganthony afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT thienchristopher afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT priestemma afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT morganmurraydonna afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT kesarisantosh afeasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT murphymichael feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT dowlinganthony feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT thienchristopher feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT priestemma feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT morganmurraydonna feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia
AT kesarisantosh feasibilitystudyofthenativisvoyagerdeviceinpatientswithrecurrentglioblastomainaustralia

Ejemplares similares